EX-10.1
from 8-K
7 pages
July 29, 2024 Dear David: We Are Pleased to Confirm Our Offer of Employment With Armata Pharmaceuticals, Inc. (The “Company”) in the Position of Senior Vice President, Finance, Effective 16 August 2024, (The “Effective Date”) on the Terms Set Forth in This Letter Agreement (The “Agreement”)
12/34/56
EX-10.2
from 8-K
9 pages
1. Position. as Vice President, Clinical Development, You Will Be Responsible for Managing the Clinical Research and Development and All Clinical Trial Programs for the Company. You Will Report Directly to the President and Chief Development Officer of the Company. You Agree to Devote Your Full Business Time and Attention to Your Work for the Company. Except Upon the Prior Written Consent of the Board of Directors of the Company (The “Board”), You Will Not, During Your Employment With the Company, (I) Accept or Maintain Any Other Employment, or (II) Engage, Directly or Indirectly, in Any Other Business Activity (Whether or Not Pursued for Pecuniary Advantage) That Might Interfere With Your Duties and Responsibilities as a Company Employee or Create a Conflict of Interest With the Company. 2. Salary. Your Initial Base Salary Will Be $380,000 Per Year, Less Applicable Withholdings. Your Salary Will Be Reviewed From Time to Time by the Board or Its Compensation Committee and May Be Adjusted in the Sole Discretion of the Board or Its Compensation Committee
12/34/56
EX-10.28
from 10-K
7 pages
August 30, 2023 Dear Richard: We Are Pleased to Confirm Our Offer of Employment With Armata Pharmaceuticals, Inc. (The “Company”) in the Position of Vice President, Corporate Controller, Effective September 5, 2023 (The “Effective Date”), on the Terms Set Forth in This Letter Agreement (The “Agreement”).
12/34/56
EX-10.2
from 8-K
6 pages
March 28, 2022 Erin Butler 4503 Glencoe Avenue Marina Del Rey, Ca 90292 Dear Erin: We Are Pleased to Confirm Our Offer of Continued Employment With Armata Pharmaceuticals, Inc. (The “Company”) in the Position of Vice President of Finance and Administration, Effective April 1, 2022, on the Terms Set Forth in This Letter Agreement (The “Agreement”)
12/34/56